blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1

This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1



Sunday 23 January 2011

Pharma sued by 23,600 persons over 30 years NO case went to trial !

(The only winners, it seems, are the fat cat lawyers)




here is an Atypical fat cat 
but there are many others







"
In a succession of major English cases from the mid 1970’s, a total of around 23,600 claimants brought claims in a succession of multiparty claims against manufacturers involving DTP vaccine, Opren, Myodil contrast media, benzodiazepine tranqullizers and the Norplant subcutaneous contraceptive (Hodges, 1999). However, no case proceeded as far as a final trial on liability. The failure of the DTP vaccine, tranquillizer and Norplant litigation in the UK can be contrasted with the fact that the manufacturers settled similar claims in the USA at enormous cost in order to avoid even greater costs of years of litigation. In 2000, a case was heard relating to the failure of a condom resulting in pregnancy, but the judge held that the defendant’s in the case had never claimed that a condom was 100% effective, and therefore the claim failed. "

1 In March 2001, the first ever successful UK product-related class action (

source - http://www.ippa.ws/IPPC1/BOOK/Chapter_15.pdf
A v National Blood Authority [2001] 3 All E.R. 289) under the Consumer Protection Act strict liability was decided, when six test cases (representing a total of 114 claimants) obtained awards of up to £210,000 from Hepatitis C infection from NHS blood transfusions. Goldberg (2002) notes the implications of this case, as it was the first opportunity of its kind in the UK to assess the problem of strict medicinal product liability in the context of a multi-party action.2

No comments:

Post a Comment

Note: only a member of this blog may post a comment.